Treatments:TYKI References

From Proteopedia

Jump to: navigation, search

References For Tyrosine Kinase Inhibitor Pharmacokinetics[1][2][3][4][5][6][7][8][9][10][11][12]

  1. ↑ D. Smith et al. Br J Clin Pharmacol. 2009 April; 67(4): 421–426.
  2. ↑ R. Khosravan, et al. General Poster Session, Developmental Therapeutics: Cytotoxic Chemotherapy, J Clin Oncol 26: 2008 (May 20 suppl; abstr 2578)
  3. ↑ Lathia C, Lettieri J, Cihon F, Gallentine M, Radtke M, Sundaresan P. Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics. Cancer Chemother Pharmacol. 2006 May;57(5):685-92. Epub 2005 Aug 25. PMID:16133532 doi:10.1007/s00280-005-0068-6
  4. ↑ Brendel E, Ludwig M, Lathia C, Robert C, Ropert S, Soria JC, Armand JP. Pharmacokinetic results of a phase I trial of sorafenib in combination with dacarbazine in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2010 Sep 7. PMID:20821331 doi:10.1007/s00280-010-1423-9
  5. ↑ Boven E, Massard C, Armand JP, Tillier C, Hartog V, Brega NM, Countouriotis AM, Ruiz-Garcia A, Soria JC. A phase I, dose-finding study of sunitinib in combination with irinotecan in patients with advanced solid tumours. Br J Cancer. 2010 Sep 28;103(7):993-1000. Epub 2010 Aug 17. PMID:20717111 doi:10.1038/sj.bjc.6605852
  6. ↑ Hamilton M, Wolf JL, Rusk J, Beard SE, Clark GM, Witt K, Cagnoni PJ. Effects of smoking on the pharmacokinetics of erlotinib. Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2166-71. PMID:16609030 doi:10.1158/1078-0432.CCR-05-2235
  7. ↑ Bergman E, Forsell P, Persson EM, Knutson L, Dickinson P, Smith R, Swaisland H, Farmer MR, Cantarini MV, Lennernas H. Pharmacokinetics of gefitinib in humans: the influence of gastrointestinal factors. Int J Pharm. 2007 Aug 16;341(1-2):134-42. Epub 2007 Apr 6. PMID:17482782 doi:10.1016/j.ijpharm.2007.04.002
  8. ↑ D. Smith et al. Br J Clin Pharmacol. 2009 April; 67(4): 421–426.
  9. ↑ Ramanathan RK, Egorin MJ, Takimoto CH, Remick SC, Doroshow JH, LoRusso PA, Mulkerin DL, Grem JL, Hamilton A, Murgo AJ, Potter DM, Belani CP, Hayes MJ, Peng B, Ivy SP. Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group. J Clin Oncol. 2008 Feb 1;26(4):563-9. PMID:18235115 doi:10.1200/JCO.2007.11.0304
  10. ↑ Bornhauser M, Pursche S, Bonin M, Freiberg-Richter J, Jenke A, Illmer T, Ehninger G, Schleyer E. Elimination of imatinib mesylate and its metabolite N-desmethyl-imatinib. J Clin Oncol. 2005 Jun 1;23(16):3855-6; author reply 3857-8. PMID:15923584 doi:10.1200/JCO.2005.05.246
  11. ↑ Yin OQ, Gallagher N, Tanaka C, Fisher D, Sethuraman V, Zhou W, Lin TH, Heuman D, Schran H. Effects of hepatic impairment on the pharmacokinetics of nilotinib: an open-label, single-dose, parallel-group study. Clin Ther. 2009;31 Pt 2:2459-69. PMID:20110053 doi:10.1016/j.clinthera.2009.11.015
  12. ↑ Johnson FM, Bekele BN, Feng L, Wistuba I, Tang XM, Tran HT, Erasmus JJ, Hwang LL, Takebe N, Blumenschein GR, Lippman SM, Stewart DJ. Phase II study of dasatinib in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2010 Oct 20;28(30):4609-15. Epub 2010 Sep 20. PMID:20855820 doi:10.1200/JCO.2010.30.5474

Proteopedia Page Contributors and Editors (what is this?)

David Canner

Retrieved from "http://proteopedia.org/wiki/index.php/Treatments:TYKI_References"
Personal tools